Member Info for Bankruptstock

Said it a few weeks ago this will be back at 1.50p and some said are the directors thick buying at 2.2p. No they are smart they got people to buy knowing it would be back to 1.5p

Could be a time to top it it does a sit did briefly hit 4.8p when it was last at these levels

NHS England do not make the decision it’s a NICE recommendation and individual trusts to decide if they want it

Given how long it take to get seen in A&E and then get a bed, the 72 hours covered here sounds ideal. We also see how GDR is finally making the real world progress its shareholders have been waiting on.

The director buys you can take with a pinch of salt they had no choice as they wanted to appease the shareholders that they had confidence in the product.

Couple of big sells this morning people taking a few hundred pounds profit

What will it take for it to go up?

Hardly any buys for supposed good news

Market agrees with guy it’s share price has gone down it was expecting a large contract not a few units.

Has done absolute nothing for the share price. Who will be first to say what till American market opens.

It’s not good news as the transformation team focus will be on existing services and not new innovations until they have for the foundations right. GDR will not now get a contract until the end of the restructure if they get one at all

What news? The only news we need is a nhs contract that’s worth more than a few quid.

Hope you are right jimi as I am down 40k at present waiting till May if it hasn’t moved then I will take the hit which will be softened on my gains from some American stocks before xmas

Genedrive plc (ticker: GDR) is a UK-based company specializing in molecular diagnostics. As of March 7, 2025, its stock price was 2.01p, with a market capitalization of approximately £11.13 million. 

Over the past year, Genedrive’s share price has experienced significant volatility, reaching a high of 8.00p and a low of 1.21p.  This reflects a substantial decline from its peak, indicating potential challenges.

Financially, the company reported revenues of £501,000 over the last 12 months, with net losses totaling £7.08 million. This resulted in a loss per share of 0.05p.  Such figures suggest ongoing profitability challenges.

Analyst evaluations also present concerns. StockInvest.us issued a negative assessment, citing multiple sell signals and a declining trend, leading to a recommendation against purchasing the stock.  Additionally, Simply Wall St highlighted a significant 87.5% decrease in share price over the past year, further emphasizing potential risks. 

Given these factors—marked share price volatility, ongoing financial losses, and negative analyst sentiments—investors should approach Genedrive plc with caution. It’s advisable to conduct thorough research and consider consulting a financial advisor before making any investment decisions.

There are no institutional investors of this share even peel have now sold all theirs. A contract is required but until labour has completed its long term plan for the nhs there will be no news.

Foolish move topping up when it’s going to be offered at 1p a share to retail very soon.

It’s all over for gdr and we shareholders have been stuffed like a turkey at Xmas

It’s all or nothing now only a newsletter can save the shareholders

In the summer went it was at this level it shot up 800% could do the same again

Is he like emerald?